[EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
申请人:ABBVIE INC
公开号:WO2016168641A1
公开(公告)日:2016-10-20
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
[EN] INDAZOLONES AS MODULATORS OF TNF SIGNALING<br/>[FR] INDAZOLONES UTILISÉES EN TANT QUE MODULATEURS DE LA SIGNALISATION DU TNF
申请人:ABBVIE INC
公开号:WO2016168633A1
公开(公告)日:2016-10-20
The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT
申请人:Tonogaki Keisuke
公开号:US20130184240A1
公开(公告)日:2013-07-18
Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula:
its pharmaceutically acceptable salt, or a solvate thereof,
wherein
a group represented by the formula:
is a group represented by the formula:
R
1
is each independently halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like;
m is an integer of 0 to 3;
R
2
is hydrogen, or substituted or unsubstituted alkyl;
X is —O—; and
Y is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
2-Aminopyrimidine derivatives and their medical use
申请人:Bollbuck Birgit
公开号:US20070043048A1
公开(公告)日:2007-02-22
A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.
The present invention provides novel phenicol derivatives of formula I
their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.